Topic: Alzheimer's disease

This Keystone Symposium integrates fundamental mechanisms, precision diagnostics, and therapeutic development for Alzheimer's disease, non-Alzheimer dementias, and other neurodegenerative disorders. Joint programming with the Neural-Immune Interactions meeting connects disease mechanisms and clinical strategy with immune modulation of central nervous system biology.

Bryce Mander presents research on early sleep biomarkers associated with Alzheimer's disease pathophysiology and memory impairment. The William C. Dement Seminar connects sleep and circadian neuroscience with neurodegeneration, cognition and clinically relevant approaches to detecting disease-related change.

Ai2 is recruiting a postdoctoral Young Investigator for CellOLMo, a collaboration using open language models with single-cell brain data. The researcher will develop multimodal models that combine gene-expression data and text, evaluate biological language grounding on the SEA-AD Alzheimer's disease atlas, build donor- and brain-region-level representations, and release resulting models, code, data, and research artifacts openly.

Parallel Squared Technology Institute is recruiting scientist and senior-scientist candidates to use single-cell proteomics to investigate protein dysfunction in Alzheimer's disease and related neurodegenerative conditions. The work spans human brain tissue, molecular mechanisms, single-cell analysis, and computational biology in an interdisciplinary team.

It is challenging to create chemical-induced models of Alzheimer’s disease without using genetically bred animals. Intracerebroventricular (ICV) streptozocin (STZ) administration at a sub-diabetogenic dose can serve as a viable model for cognitive impairment associated with Alzheimer's disease via a disruption of glucose and energy metabolism in the brain, accompanied by oxidative stress and a concurrent impact on cognitive function. The aim of this study is to evaluate the behavioral results of once or twice injections of the ICV STZ administration methods. ICV guide cannulas were placed unil

OBJECTIVE: Alzheimer's disease (AD) stands as the prevalent neurodegenerative condition globally, characterized by symptoms such as memory loss, language difficulties, disorientation, diminished motivation, self-neglect, mood fluctuations, and behavioral challenges. Despite its widespread impact, the precise cellular mechanisms underlying the onset of AD remain elusive. This study aims to uncover potential pathophysiological contributors to AD by analyzing gene expression levels through bioinformatics approaches. METHODS: GSE129296 dataset downloaded from Gene Expression Omnibus (GEO) database

Dementia, a complex, incurable clinical syndrome marked by progressive cognitive decline, encompasses various types, with Alzheimer's disease (AD) being the most prevalent. The annual increase in AD cases underscores the urgency for innovative antidementia treatments. Mansorin A (MA) and mansonone G (MG) exhibit antioxidant effects on the central nervous system. Given the close association between oxidative stress and AD pathology, MA and MG might alleviate AD-like symptoms. To investigate the anti-dementia potential of MA and MG, the promnesic, anxiolytic, and antioxidant potential of MA and